Dominique Babuty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10491749/publications.pdf

Version: 2024-02-01

63 papers 5,129 citations

147801 31 h-index 58 g-index

66 all docs 66
docs citations

66 times ranked 5005 citing authors

#	Article	IF	CITATIONS
1	Sudden Cardiac Arrest Associated with Early Repolarization. New England Journal of Medicine, 2008, 358, 2016-2023.	27.0	1,308
2	Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome. Circulation, 2006, 114, 2317-2324.	1.6	303
3	Clinical Aspects and Prognosis of Brugada Syndrome in Children. Circulation, 2007, 115, 2042-2048.	1.6	275
4	Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome. Circulation, 2013, 128, 1739-1747.	1.6	267
5	SCN5A Mutations and the Role of Genetic Background in the Pathophysiology of Brugada Syndrome. Circulation: Cardiovascular Genetics, 2009, 2, 552-557.	5.1	262
6	Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 828-835.	2.8	255
7	Interventricular and intraventricular dyssynchrony in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2002, 40, 2022-2030.	2.8	189
8	Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing. Journal of the American College of Cardiology, 2002, 40, 1645-1652.	2.8	179
9	Heart Rate Variability in Idiopathic Dilated Cardiomyopathy: Characteristics and Prognostic Value. Journal of the American College of Cardiology, 1997, 30, 1009-1014.	2.8	159
10	Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 1203-1207.	2.8	146
11	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1278-1287.	1.5	139
12	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation, 2019, 140, 293-302.	1.6	131
13	Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thrombosis and Haemostasis, 2010, 103, 833-840.	3.4	104
14	Progressive Cardiac Conduction Defect is the Prevailing Phenotype in Carriers of a Brugada Syndrome <i>SCN5A</i> Mutation. Journal of Cardiovascular Electrophysiology, 2006, 17, 270-275.	1.7	90
15	Statin therapy and atrial fibrillation. Current Opinion in Cardiology, 2013, 28, 7-18.	1.8	90
16	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm, 2016, 13, 1274-1282.	0.7	89
17	How to define valvular atrial fibrillation?. Archives of Cardiovascular Diseases, 2015, 108, 530-539.	1.6	86
18	Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter. Chest, 2011, 140, 911-917.	0.8	70

#	Article	IF	CITATIONS
19	Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. International Journal of Cardiology, 2011, 150, 54-58.	1.7	67
20	Role of Electrophysiological Studies in Predicting Risk of Ventricular Arrhythmia in Early Repolarization Syndrome. Journal of the American College of Cardiology, 2015, 65, 151-159.	2.8	63
21	Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. European Heart Journal, 2017, 38, ehw569.	2.2	59
22	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?. Stroke, 2016, 47, 1831-1836.	2.0	59
23	Reliability of QRS duration and morphology on surface electrocardiogram to identify ventricular dyssynchrony in patients with idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2003, 92, 341-344.	1.6	58
24	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
25	Prognostic value of CHA ₂ DS ₂ -VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. European Heart Journal, 2015, 36, 1822.2-1830.	2.2	53
26	Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences, 2018, 19, 976.	4.1	52
27	Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Scientific Reports, 2016, 6, 34357.	3.3	45
28	Long-term prognostic value of time domain analysis of signal-averaged electrocardiography in idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2000, 85, 618-623.	1.6	43
29	Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. European Journal of Heart Failure, 2004, 6, 181-185.	7.1	43
30	Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity. Heart Rhythm, 2017, 14, 1442-1448.	0.7	36
31	Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. JAMA Neurology, 2018, 75, 573.	9.0	32
32	Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. Cardiovascular Research, 2012, 95, 59-68.	3.8	31
33	The psychological impact of implantable cardioverter defibrillator implantation on Brugada syndrome patients. Europace, 2011, 13, 1034-1039.	1.7	30
34	The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications. Heart, 2012, 98, 291-296.	2.9	28
35	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. American Journal of Cardiology, 2016, 118, 700-707.	1.6	22
36	Segmental wall motion abnormalities in idiopathic dilated cardiomyopathy and their effect on prognosis. American Journal of Cardiology, 2004, 93, 1504-1509.	1.6	21

#	Article	IF	CITATIONS
37	Electrical storm reversible by isoproterenol infusion in a striking case of early repolarization. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 123-127.	1.3	21
38	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	21
39	Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PLoS ONE, 2018, 13, e0201517.	2.5	20
40	Prognosis in Patients Hospitalized With Permanent and Nonpermanent Atrial Fibrillation in Heart Failure. American Journal of Cardiology, 2014, 113, 1189-1195.	1.6	19
41	Ventricular Dyssynchrony and Risk Markers of Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy:. A Study with Phase Analysis of Angioscintigraphy. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 352-356.	1.2	17
42	Value of the sodium-channel blocker challenge in Brugada syndrome. International Journal of Cardiology, 2017, 245, 178-180.	1.7	17
43	Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. Journal of Translational Medicine, 2018, 16, 299.	4.4	11
44	Prophylactic implantable cardioverter-defibrillator in the very elderly. Europace, 2019, 21, 1063-1069.	1.7	11
45	Insufficiency of electrocardiogram alone in predicting infrahisian abnormalities in patients with type 1 myotonic dystrophy. International Journal of Cardiology, 2014, 172, 625-627.	1.7	8
46	Incomplete recovery of mechanical and endocrine left atrial functions one month after electrical cardioversion for persistent atrial fibrillation: a pilot study. Journal of Translational Medicine, 2014, 12, 51.	4.4	7
47	Different Criteria of Cardiac Resynchronization Therapy and Their Prognostic Value for Worsening Heart Failure or Major Arrhythmic Events in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2006, 97, 393-399.	1.6	6
48	Severe recurrent vasovagal syncope and multidisciplinary rehabilitation: A prospective randomized pilot study. International Journal of Cardiology, 2015, 187, 658-659.	1.7	4
49	Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Advances in Therapy, 2017, 34, 1283-1290.	2.9	4
50	Leadless cardiac pacemaker implantation in patient with active tricuspid endocarditis. Europace, 2021, 23, 1794-1794.	1.7	4
51	Interventricular delay measurement using equilibrium radionuclide angiography before resynchronization therapy should be performed outside the area of segmental wall motion abnormalities. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 239-244.	6.4	3
52	Left Retropectoral Axillary Implantation of Defibrillators in Young Women. Annals of Thoracic Surgery, 2012, 93, 331-333.	1.3	3
53	How should we treat patients with atrial fibrillation and a CHADS ₂ score of 1?. Therapy: Open Access in Clinical Medicine, 2010, 7, 111-115.	0.2	1
54	Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. Archives of Cardiovascular Diseases, 2017, 110, 590-598.	1.6	1

#	Article	IF	CITATIONS
55	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from) Tj ETQq $1\ 1$	0.784314 1.6	rgBT /Overlo
56	Atrioventricular Nodal Reentrant Tachycardia Ablation Using Mini-Electrode Recordings. Journal of Clinical Medicine, 2022, $11,282$.	2.4	1
57	Physiological pacing with a DF‹ single chamber defibrillator in a patient with permanent atrial fibrillation and heart block: A case report. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	1
58	How to upgrade a leadless pacemaker to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 2578-2581.	1.7	0
59	End-of-service management of leadless cardiac pacemakers: a case report. Europace, 2019, 21, 1245-1245.	1.7	0
60	Distalâ€toâ€proximal delay for ablation of premature ventricular contractions. Journal of Cardiovascular Electrophysiology, 2019, 30, 205-211.	1.7	0
61	Number of electrocardiogram leads in the diagnosis of spontaneous Brugada syndrome. Archives of Cardiovascular Diseases, 2020, 113, 152-158.	1.6	0
62	The ICâ€D score for predicting prophylactic cardioverterâ€defibrillator implantation following acute myocardial infarction. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 973-979.	1.2	0
63	Statin and Atrial Fibrilation: When does it work?. Journal of Atrial Fibrillation, 2012, 5, 443.	0.5	0